Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) Interest & Investment Income (2018 - 2025)

X4 Pharmaceuticals' Interest & Investment Income history spans 8 years, with the latest figure at $2.0 million for Q4 2025.

  • For Q4 2025, Interest & Investment Income rose 56.67% year-over-year to $2.0 million; the TTM value through Dec 2025 reached $4.6 million, down 20.68%, while the annual FY2025 figure was $4.6 million, 20.68% down from the prior year.
  • Interest & Investment Income reached $2.0 million in Q4 2025 per XFOR's latest filing, up from $901000.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $2.0 million in Q4 2025 to a low of $2000.0 in Q1 2021.
  • Average Interest & Investment Income over 5 years is $757800.0, with a median of $868000.0 recorded in 2023.
  • Peak YoY movement for Interest & Investment Income: plummeted 99.32% in 2021, then soared 27733.33% in 2023.
  • A 5-year view of Interest & Investment Income shows it stood at $3000.0 in 2021, then surged by 6500.0% to $198000.0 in 2022, then soared by 629.8% to $1.4 million in 2023, then fell by 12.32% to $1.3 million in 2024, then surged by 56.67% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Interest & Investment Income are $2.0 million (Q4 2025), $901000.0 (Q3 2025), and $665000.0 (Q2 2025).